The blood-brain barrier: Structure, function and therapeutic approaches to cross it
暂无分享,去创建一个
E. Ramos-Fernández | M. Bosch-Morató | M. Tajes | A. Eraso-Pichot | X. Fernàndez-Busquets | Jaume Roquer | Xavier Fernàndez-Busquets | F. J. Muñoz | J. Roquer | Marta Tajes | Eva Ramos-Fernández | Xian Weng-Jiang | Mònica Bosch-Morató | Biuse Guivernau | Abel Eraso-Pichot | Bertrán Salvador | Francisco J Muñoz | B. Guivernau | Bertran Salvador | Xian Weng-Jiang | Eva Ramos-Fernández | Biuse Guivernau | Mónica Bosch-Morató | Weng-Jiang Xian
[1] Henry Brem,et al. Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[2] A. Ávila-Flores,et al. MAGUK proteins: structure and role in the tight junction. , 2000, Seminars in cell & developmental biology.
[3] G. Pitarresi,et al. Nanoparticulate Systems for Drug Delivery and Targeting to the Central Nervous System , 2011, CNS neuroscience & therapeutics.
[4] Rachel C Brown,et al. Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells , 2007, Brain Research.
[5] A. Schatzlein,et al. Strategies to deliver peptide drugs to the brain. , 2014, Molecular pharmaceutics.
[6] R. Keep,et al. Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier , 2008, Current neuropharmacology.
[7] W. Pardridge,et al. Blood-brain barrier transcytosis of insulin in developing rabbits , 1987, Brain Research.
[8] Jean-Christophe Olivier,et al. Drug transport to brain with targeted nanoparticles , 2011, NeuroRX.
[9] K. Furuuchi,et al. Glial cell line-derived neurotrophic factor induces barrier function of endothelial cells forming the blood-brain barrier. , 1999, Biochemical and biophysical research communications.
[10] B. Engelhardt,et al. The blood–brain and the blood–cerebrospinal fluid barriers: function and dysfunction , 2009, Seminars in Immunopathology.
[11] L. Rubin,et al. The cell biology of the blood-brain barrier. , 1999, Annual review of neuroscience.
[12] M. Takeichi,et al. Transmembrane control of cadherin-mediated cell adhesion: a 94 kDa protein functionally associated with a specific region of the cytoplasmic domain of E-cadherin. , 1989, Cell regulation.
[13] Char-Huei Lai,et al. The critical component to establish in vitro BBB model: Pericyte , 2005, Brain Research Reviews.
[14] D. Kwiatkowski,et al. Tumour necrosis factor, fever and fatality in falciparum malaria. , 1990, Immunology letters.
[15] J M Scherrmann,et al. Drug delivery to brain via the blood-brain barrier. , 2002, Vascular pharmacology.
[16] K. Elisevich,et al. Vascularization and microvascular permeability in solid versus cell-suspension embryonic neural grafts. , 1994, Journal of neurosurgery.
[17] N J Abbott,et al. Electrical resistance across the blood‐brain barrier in anaesthetized rats: a developmental study. , 1990, The Journal of physiology.
[18] I. Wilhelm,et al. In vitro models of the blood-brain barrier. , 2011, Acta neurobiologiae experimentalis.
[19] E. Pasquale,et al. Tyrosine phosphorylated proteins in different tissues during chick embryo development , 1988, The Journal of cell biology.
[20] Natalia Vykhodtseva,et al. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. , 2008, Ultrasonics.
[21] P. Dickson. Delivering drugs to the central nervous system: an overview , 2012, Drug Delivery and Translational Research.
[22] Transplanting bone-marrow stem cells in the central nervous system. , 2000, Haematologica.
[23] Lucienne Juillerat-Jeanneret,et al. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? , 2008, Drug discovery today.
[24] C P Ponting,et al. PDZ Domains: Targeting signalling molecules to sub‐membranous sites , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.
[25] M. Frank. The reticuloendothelial system and bloodstream clearance. , 1993, The Journal of laboratory and clinical medicine.
[26] G. Lapin,et al. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. , 1999, Microvascular research.
[27] S. Moochhala,et al. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. , 2008, Biopolymers.
[28] Yan Zhang,et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[29] B. Testa,et al. Lessons learned from marketed and investigational prodrugs. , 2004, Journal of medicinal chemistry.
[30] W. Pardridge. New approaches to drug delivery through the blood-brain barrier. , 1994, Trends in biotechnology.
[31] P. Cancilla,et al. Neutral Amino Acid Transport Properties of Cerebral Endothelial Cells in Vitro , 1983, Journal of neuropathology and experimental neurology.
[32] E. Neuwelt. Mechanisms of Disease: The Blood-Brain Barrier , 2004, Neurosurgery.
[33] Zhirong Zhang,et al. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. , 2011, International journal of pharmaceutics.
[34] J. Bading,et al. Cerebrovascular Accumulation and Increased Blood‐Brain Barrier Permeability to Circulating Alzheimer's Amyloid β Peptide in Aged Squirrel Monkey with Cerebral Amyloid Angiopathy , 1998, Journal of neurochemistry.
[35] I. Fichtner,et al. Improving the transport of chemotherapeutic drugs across the blood–brain barrier , 2011, Expert review of clinical pharmacology.
[36] A. Trapani,et al. In vitro evaluation on a model of blood brain barrier of idebenone-loaded solid lipid nanoparticles. , 2012, Journal of nanoscience and nanotechnology.
[37] B. McEwen,et al. Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. , 2001, Annual review of pharmacology and toxicology.
[38] H. Okada,et al. Intranasal Delivery of Camptothecin-Loaded Tat-Modified Nanomicells for Treatment of Intracranial Brain Tumors , 2012, Pharmaceuticals.
[39] Anna Forsby,et al. Blood-brain barrier in vitro models and their application in toxicology - The report and recommendations of ECVAM workshop 49 , 2004 .
[40] C. Ropert,et al. Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. , 1992, Biomaterials.
[41] W. Scheld,et al. Drug delivery to the central nervous system: general principles and relevance to therapy for infections of the central nervous system. , 1989, Reviews of infectious diseases.
[42] M. Hatzfeld. The p120 family of cell adhesion molecules. , 2005, European journal of cell biology.
[43] E. Lo,et al. Junctional complexes of the blood–brain barrier: permeability changes in neuroinflammation , 2002, Progress in Neurobiology.
[44] Wolfgang Löscher,et al. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases , 2005, Progress in Neurobiology.
[45] B. Engelhardt. Development of the blood-brain barrier , 2003, Cell and Tissue Research.
[46] B. Barres,et al. Induction of Astrocyte Differentiation by Endothelial Cells , 2001, The Journal of Neuroscience.
[47] Coecke Sandra,et al. Blood-Brain Barrier invitro Models and their Application in Toxicology. , 2004 .
[48] M. Brightman,et al. Nonpermeable and permeable vessels of the brain. , 1992, NIDA research monograph.
[49] M. Ricci,et al. Solid lipid nanoparticles for targeted brain drug delivery. , 2007, Advanced drug delivery reviews.
[50] T. Mayumi,et al. Preparation of glial extracellular matrix: a novel method to analyze glial-endothelial cell interaction. , 1997, Brain research. Brain research protocols.
[51] Hyun Seok Song,et al. SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier , 2003, Nature Medicine.
[52] Hiroshi Yamamoto,et al. Induction of various blood‐brain barrier properties in non‐neural endothelial cells by close apposition to co‐cultured astrocytes , 1997, Glia.
[53] R. Janzer,et al. Astrocytes induce blood–brain barrier properties in endothelial cells , 1987, Nature.
[54] R B Wysolmerski,et al. Myosin light chain kinase-regulated endothelial cell contraction: the relationship between isometric tension, actin polymerization, and myosin phosphorylation , 1995, The Journal of cell biology.
[55] I. Tamai,et al. Transporter-mediated permeation of drugs across the blood-brain barrier. , 2000, Journal of pharmaceutical sciences.
[56] A. Verkman,et al. Aquaporin water channels and endothelial cell function * , 2002, Journal of anatomy.
[57] W. Pardridge,et al. Combination stroke therapy in the mouse with blood–brain barrier penetrating IgG–GDNF and IgG–TNF decoy receptor fusion proteins , 2013, Brain Research.
[58] J. Stow,et al. Protein trafficking and polarity in kidney epithelium: from cell biology to physiology. , 1996, Physiological reviews.
[59] Peter Ramge,et al. Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.
[60] Yuanjun Zhu,et al. Neuroprotective Effect of TAT-14-3-3ε Fusion Protein against Cerebral Ischemia/Reperfusion Injury in Rats , 2014, PloS one.
[61] D. A. Quarles,et al. Progress and problems , 1953, Electrical Engineering.
[62] D. Shore,et al. Cingulin Contains Globular and Coiled-Coil Domains and Interacts with Zo-1, Zo-2, Zo-3, and Myosin , 1999, The Journal of cell biology.
[63] R. Thorne,et al. Quantitative analysis of the olfactory pathway for drug delivery to the brain , 1995, Brain Research.
[64] N. Kawai,et al. Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability, and cell survival in a rat model. , 1996, Journal of neurosurgery.
[65] W. Frey,et al. Delivery of Neurotrophic Factors to the Central Nervous System , 2001, Clinical pharmacokinetics.
[66] V. Labhasetwar,et al. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. , 2008, Biomaterials.
[67] H. Steinbusch,et al. Delivery of peptide and protein drugs over the blood–brain barrier , 2009, Progress in Neurobiology.
[68] G. Bazzoni. Endothelial tight junctions: permeable barriers of the vessel wall , 2005, Thrombosis and Haemostasis.
[69] A. Schinkel,et al. P-Glycoprotein, a gatekeeper in the blood-brain barrier. , 1999, Advanced drug delivery reviews.
[70] L. Rubin,et al. A cell culture model of the blood-brain barrier , 1991, The Journal of cell biology.
[71] E. Hansson,et al. Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.
[72] Qin He,et al. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[73] G. Miller. Breaking Down Barriers , 2002, Science.
[74] M. Ricci,et al. Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue? , 2006, Current medicinal chemistry.
[75] N. Abbott,et al. Astrocyte–endothelial interactions and blood–brain barrier permeability * , 2002 .
[76] W. Geldenhuys,et al. Novel models for assessing blood–brain barrier drug permeation , 2012, Expert opinion on drug metabolism & toxicology.
[77] B. Gumbiner,et al. Structure, biochemistry, and assembly of epithelial tight junctions. , 1987, The American journal of physiology.
[78] L. Rubin,et al. Cell adhesion, cell junctions and the blood—brain barrier , 1996, Current Opinion in Neurobiology.
[79] M. Wiley,et al. Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: a study using quail--chick transplantation chimeras. , 1981, Developmental biology.
[80] S Esser,et al. Cell confluence regulates tyrosine phosphorylation of adherens junction components in endothelial cells. , 1997, Journal of cell science.
[81] Elisabetta Dejana,et al. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. , 2004, Physiological reviews.
[82] S. Hemmerich,et al. Vascular Endothelial Junction-associated Molecule, a Novel Member of the Immunoglobulin Superfamily, Is Localized to Intercellular Boundaries of Endothelial Cells* , 2000, The Journal of Biological Chemistry.
[83] W H Oldendorf,et al. Kinetic analysis of blood-brain barrier transport of amino acids. , 1975, Biochimica et biophysica acta.
[84] R. Langer,et al. A theoretical model of erosion and macromolecular drug release from biodegrading microspheres. , 1997, Journal of pharmaceutical sciences.
[85] H. Galla,et al. Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. , 2011, Biochemical and biophysical research communications.
[86] R. Egleton,et al. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability , 2001, Peptides.
[87] W. Pardridge,et al. Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vector. , 1990, The Journal of pharmacology and experimental therapeutics.
[88] R. Bendayan,et al. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. , 2001, Pharmacological reviews.
[89] D D Allen,et al. Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier , 2002, Drug development and industrial pharmacy.
[90] M. Salcman,et al. Transcytotic pathway for blood-borne protein through the blood-brain barrier. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[91] A. Trapani,et al. Recent advances in medicinal chemistry and pharmaceutical technology--strategies for drug delivery to the brain. , 2009, Current topics in medicinal chemistry.
[92] J. Firth,et al. Immunohistochemical localization of adherens junction components in blood-brain barrier microvessels of the rat. , 1993, Journal of cell science.
[93] A. Petrillo,et al. Blood‐Brain Barrier Disruption for the Treatment of Malignant Brain Tumors: The National Program , 1998, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.
[94] P. Vassalli,et al. Tumor‐Necrosis Factor and other Cytokines in Cerebral Malaria: Experimental and Clinical Data , 1989, Immunological reviews.
[95] P Delorme,et al. An Easier, Reproducible, and Mass‐Production Method to Study the Blood–Brain Barrier In Vitro , 1990, Journal of neurochemistry.
[96] W. Pardridge,et al. Brain Delivery of Biotin Bound to a Conjugate of Neutral Avidin and Cationized Human Albumin , 1994, Pharmaceutical Research.
[97] D. Lasič. Novel applications of liposomes. , 1998, Trends in biotechnology.
[98] T. Bui,et al. Multiple protein interactions involving proposed extracellular loop domains of the tight junction protein occludin. , 2005, Molecular biology of the cell.
[99] N. Yamamoto,et al. Induction of blood–brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors , 1999, Neuroscience Research.
[100] Holger Gerhardt,et al. Lack of Pericytes Leads to Endothelial Hyperplasia and Abnormal Vascular Morphogenesis , 2001, The Journal of cell biology.
[101] Y. Olsson,et al. Observations on exsudation of fibronectin, fibrinogen and albumin in the brain after carotid infusion of hyperosmolar solutions , 2004, Acta Neuropathologica.
[102] M. Fukui,et al. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. , 1996, Neurosurgery.
[103] C. Coopersmith,et al. Epithelial cells , 1991 .
[104] K. Nakanishi,et al. Astrocytic contributions to blood-brain barrier (BBB) formation by endothelial cells: A possible use of aortic endothelial cell for In vitro BBB model , 1996, Neurochemistry International.
[105] Manini Patel,et al. Solid Lipid Nanoparticles , 2014 .
[106] L. Rubin,et al. Occludin as a possible determinant of tight junction permeability in endothelial cells. , 1997, Journal of cell science.
[107] Hanseup Kim,et al. Characterization of a microfluidic in vitro model of the blood-brain barrier (μBBB). , 2012, Lab on a chip.
[108] V. Torchilin,et al. Drug targeting. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[109] S. Gloor,et al. Co-culture blood-brain barrier models and their use for pharmatoxicological screening. , 1997, Toxicology in vitro : an international journal published in association with BIBRA.
[110] R. Udomsangpetch,et al. In vitro study of malaria parasite induced disruption of blood-brain barrier. , 2005, Biochemical and biophysical research communications.
[111] D. V. Kohli,et al. Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil , 2005, Journal of drug targeting.
[112] U. Christians,et al. Ultrasound-Induced Mild Hyperthermia as a Novel Approach to Increase Drug Uptake in Brain Microvessel Endothelial Cells , 2002, Pharmaceutical Research.
[113] Li Hai,et al. Design, synthesis and biological evaluation of multivalent glucosides with high affinity as ligands for brain targeting liposomes. , 2014, European journal of medicinal chemistry.
[114] I. Blasig,et al. In Search of the Astrocytic Factor(s) Modulating Blood–Brain Barrier Functions in Brain Capillary Endothelial Cells In Vitro , 2005, Cellular and Molecular Neurobiology.
[115] S. K. Malhotra,et al. Reactive astrocytes: cellular and molecular cues to biological function , 1997, Trends in Neurosciences.
[116] M. Saitoh,et al. Localization of 7H6 tight junction-associated antigen along the cell border of vascular endothelial cells correlates with paracellular barrier function against ions, large molecules, and cancer cells. , 1996, Experimental cell research.
[117] W. Pardridge,et al. Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[118] Te-Wei Lee,et al. In Vitro and in Vivo Evaluation of Lactoferrin-Conjugated Liposomes as a Novel Carrier to Improve the Brain Delivery , 2013, International journal of molecular sciences.
[119] G. Fricker,et al. Modulation of Drug Transporters at the Blood-Brain Barrier , 2004, Pharmacology.
[120] L. Illum. Transport of drugs from the nasal cavity to the central nervous system. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[121] J. Holly,et al. The Role of Insulin-Like Growth Factor Binding Proteins , 2006, Neuroendocrinology.
[122] G. Goldstein,et al. Hexose transport in microvascular endothelial cells cultured from bovine retina. , 1983, Experimental eye research.
[123] H. Newton,et al. Advances in strategies to improve drug delivery to brain tumors , 2006, Expert review of neurotherapeutics.
[124] L. Rubin,et al. Dephosphorylation of the Cadherin-associated p100/p120 Proteins in Response to Activation of Protein Kinase C in Epithelial Cells* , 1997, The Journal of Biological Chemistry.
[125] K. Jain,et al. Use of nanoparticles for drug delivery in glioblastoma multiforme , 2007, Expert review of neurotherapeutics.
[126] I. Herman,et al. The pericyte: cellular regulator of microvascular blood flow. , 2009, Microvascular research.
[127] Robert Langer,et al. Intracranial MEMS based temozolomide delivery in a 9L rat gliosarcoma model. , 2012, Biomaterials.
[128] R. Egleton,et al. Protection against hypoxia-induced blood-brain barrier disruption: changes in intracellular calcium. , 2004, American journal of physiology. Cell physiology.
[129] R Langer,et al. Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity. , 1986, Journal of biomedical materials research.
[130] R. Bartus,et al. Intravenous Cereport (RMP-7) Enhances Delivery of Hydrophilic Chemotherapeutics and Increases Survival in Rats with Metastatic Tumors in the Brain , 2000, Pharmaceutical Research.
[131] S. B. Tiwari,et al. A review of nanocarrier-based CNS delivery systems. , 2006, Current drug delivery.
[132] S I Simon,et al. Analysis of tight junctions during neutrophil transendothelial migration. , 2000, Journal of cell science.
[133] M. Khrestchatisky,et al. Medicinal Chemistry Based Approaches and Nanotechnology‐Based Systems to Improve CNS Drug Targeting and Delivery , 2013, Medicinal research reviews.
[134] M. Schroeter,et al. Astrocytes enhance radical defence in capillary endothelial cells constituting the blood‐brain barrier , 1999, FEBS letters.
[135] N. Hogg,et al. Identification and characterisation of human Junctional Adhesion Molecule (JAM). , 1999, Molecular immunology.
[136] C. Patlak,et al. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. , 1975, The Journal of pharmacology and experimental therapeutics.
[137] V. Perry,et al. The blood-brain barrier and the inflammatory response. , 1997, Molecular medicine today.
[138] P. Lantos,et al. Hyperosmolar Opening of the Blood-Brain Barrier in the Energy-Depleted Rat Brain. Part 1. Permeability Studies , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[139] J. Kreuter. Drug targeting with nanoparticles , 1994, European Journal of Drug Metabolism and Pharmacokinetics.
[140] M. Lakomek,et al. Alkylglycerol opening of the blood–brain barrier to small and large fluorescence markers in normal and C6 glioma‐bearing rats and isolated rat brain capillaries , 2003, British journal of pharmacology.
[141] Y. Nagai,et al. PAR‐6 regulates aPKC activity in a novel way and mediates cell‐cell contact‐induced formation of the epithelial junctional complex , 2001, Genes to cells : devoted to molecular & cellular mechanisms.
[142] M. Balda,et al. Multiple domains of occludin are involved in the regulation of paracellular permeability , 2000, Journal of cellular biochemistry.
[143] Mikko Gynther,et al. Prodrug Approaches for CNS Delivery , 2008, The AAPS Journal.
[144] R. Barth,et al. Targeted delivery of methotrexate to epidermal growth factor receptor–positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates , 2006, Molecular Cancer Therapeutics.
[145] K. Maclean,et al. Neural Stem Cells Reduce Hippocampal Tau and Reelin Accumulation in Aged Ts65Dn down Syndrome Mice , 2011, Cell transplantation.
[146] J. Bulte,et al. Neural progenitor cell survival in mouse brain can be improved by co-transplantation of helper cells expressing bFGF under doxycycline control , 2013, Experimental Neurology.
[147] D. Papahadjopoulos,et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. , 1999, Pharmacological reviews.
[148] A. Rawat,et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles , 2006, Journal of drug targeting.
[149] M. Einarson. Controlled-release microchip , 1999, Nature Biotechnology.
[150] A. Schinkel,et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.
[151] S I Simon,et al. Neutrophil transendothelial migration is independent of tight junctions and occurs preferentially at tricellular corners. , 1997, Journal of immunology.
[152] P. Couraud. Infiltration of inflammatory cells through brain endothelium. , 1998, Pathologie-biologie.
[153] W. Pardridge. Recent developments in peptide drug delivery to the brain. , 1992, Pharmacology & toxicology.
[154] Hartwig Wolburg,et al. Tight junctions of the blood-brain barrier: development, composition and regulation. , 2002, Vascular pharmacology.
[155] Kwangmeyung Kim,et al. Nano-enabled delivery systems across the blood–brain barrier , 2013, Archives of Pharmacal Research.
[156] E. Neuwelt,et al. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. , 1998, Neurosurgery.
[157] A. Fadda,et al. Liposomes for brain delivery , 2013, Expert opinion on drug delivery.
[158] Qing-hui Zhou,et al. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. , 2011, Bioconjugate chemistry.
[159] N. Shaik,et al. Drug efflux transporters in the CNS. , 2003, Advanced drug delivery reviews.
[160] N. Saunders. Faculty of 1000 evaluation for Getting into the brain: approaches to enhance brain drug delivery. , 2016 .
[161] E. Snyder,et al. Neurotransplantation of stem cells genetically modified to express human dopamine transporter reduces alcohol consumption , 2010, Stem Cell Research & Therapy.
[162] G. Bonvento,et al. Structural organization of the perivascular astrocyte endfeet and their relationship with the endothelial glucose transporter: A confocal microscopy study , 1998, Glia.
[163] W. Thomas,et al. Brain macrophages: on the role of pericytes and perivascular cells , 1999, Brain Research Reviews.
[164] I. Romero,et al. Transporting therapeutics across the blood-brain barrier. , 1996, Molecular medicine today.
[165] P. A. Peterson,et al. The Roles of Claudin Superfamily Proteins in Paracellular Transport , 2001, Traffic.
[166] G. Vassal,et al. Poly(ethylene glycol)-Coated Hexadecylcyanoacrylate Nanospheres Display a Combined Effect for Brain Tumor Targeting , 2002, Journal of Pharmacology and Experimental Therapeutics.
[167] T. Davis,et al. The Blood-Brain Barrier/Neurovascular Unit in Health and Disease , 2005, Pharmacological Reviews.
[168] B. Geiger,et al. The molecular organization of endothelial cell to cell junctions: differential association of plakoglobin, beta-catenin, and alpha- catenin with vascular endothelial cadherin (VE-cadherin) , 1995, The Journal of cell biology.
[169] Amit Modgil,et al. Influence of Short-Chain Cell-Penetrating Peptides on Transport of Doxorubicin Encapsulating Receptor-Targeted Liposomes Across Brain Endothelial Barrier , 2014, Pharmaceutical Research.
[170] S. Stenglein,et al. Morphological and functional characterization of an in vitro blood–brain barrier model , 1997, Brain Research.
[171] R. Bartus,et al. Intravenous cereport (RMP-7) modifies topographic uptake profile of carboplatin within rat glioma and brain surrounding tumor, elevates platinum levels, and enhances survival. , 2000, The Journal of pharmacology and experimental therapeutics.
[172] W. Saltzman,et al. Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix. , 1994, Cancer research.
[173] M. Mayberg,et al. Mechanisms of glucose transport at the blood–brain barrier: an in vitro study , 2001, Brain Research.
[174] H. Brem,et al. New directions in the delivery of drugs and other substances to the central nervous system. , 1991, Advances in pharmacology.
[175] W. D. de Jong,et al. Drug delivery and nanoparticles: Applications and hazards , 2008, International journal of nanomedicine.
[176] K. Avgoustakis,et al. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. , 2004, Current drug delivery.
[177] J. H. Beijnen,et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.
[178] J. Lai,et al. Brain metabolism and specific transport at the blood- brain barrier after portocaval anastomosis in the rat , 1979, Brain Research.
[179] G. Miller. Drug targeting. Breaking down barriers. , 2002, Science.
[180] Sara Eyal,et al. Drug interactions at the blood-brain barrier: fact or fantasy? , 2009, Pharmacology & therapeutics.
[181] S. Tsukita,et al. Manner of Interaction of Heterogeneous Claudin Species within and between Tight Junction Strands , 1999, The Journal of cell biology.
[182] P. McCrea,et al. Purification of a 92-kDa cytoplasmic protein tightly associated with the cell-cell adhesion molecule E-cadherin (uvomorulin). Characterization and extractability of the protein complex from the cell cytostructure. , 1991, The Journal of biological chemistry.
[183] G. Turner,et al. Breaking down the blood-brain barrier: signaling a path to cerebral malaria? , 2002, Trends in parasitology.
[184] H. Hirschberg,et al. Site‐specific opening of the blood‐brain barrier , 2010, Journal of biophotonics.
[185] W. Pardridge,et al. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[186] L. Sobrevia,et al. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. , 2003, Physiological reviews.
[187] D. Begley. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. , 2004, Pharmacology & therapeutics.
[188] W. Pardridge,et al. Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain Cancer , 2004, Clinical Cancer Research.
[189] M. Takeichi,et al. p120ctn Acts as an Inhibitory Regulator of Cadherin Function in Colon Carcinoma Cells , 1999, The Journal of cell biology.
[190] P. Gaillard. Case study: to-BBB's G-Technology, getting the best from drug-delivery research with industry-academia partnerships. , 2011, Therapeutic delivery.
[191] Luca Cucullo,et al. Development of a Humanized In Vitro Blood–Brain Barrier Model to Screen for Brain Penetration of Antiepileptic Drugs , 2007, Epilepsia.